Aytu BioPharma (AYTU) vs Quantum Biopharma (QNTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aytu BioPharma (AYTU) has outperformed Quantum Biopharma (QNTM) over the past year, losing 13.5% versus a loss of 80.3%. Over five years, AYTU leads with a -96.1% price change compared with -96.7% for QNTM. Aytu BioPharma is the larger company by market cap ($22.3 million vs $19.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AYTU | QNTM |
|---|---|---|
| Share price | $2.06 | $3.05 |
| Market cap | $22.33M | $19.58M |
| 1-day change | +0.24% | -2.09% |
| YTD return | -21.15% | -57.40% |
| 1-year return | -13.50% | -80.28% |
| 5-year return | -96.13% | -96.65% |
| Forward P/E | 13.26 | — |
| EPS (TTM) | $-1.16 | $-4.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.07 | $16.36 |
| 52-week low | $1.80 | $2.07 |
| Distance from 52-week high | -33.06% | -81.39% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +370.56% | +302.96% |
| Average volume | 34.22K | 205.30K |
| Shares outstanding | 10.87M | 6.43M |
| Employees | 75 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AYTU has outperformed QNTM by 66.8 percentage points over the past year.
About Aytu BioPharma
AYTU stock →Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
About Quantum Biopharma
QNTM stock →Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments.
Health Care · Biotechnology: Pharmaceutical Preparations
AYTU vs QNTM FAQ
Which is bigger, Aytu BioPharma or Quantum Biopharma?
Aytu BioPharma (AYTU) is larger, with a market capitalization of $22.33M compared with $19.58M for Quantum Biopharma (QNTM).
Which stock has performed better over the past year, AYTU or QNTM?
AYTU returned -13.50% over the past 12 months, compared with -80.28% for QNTM (price return, excluding dividends). Past performance does not predict future results.
Are Aytu BioPharma and Quantum Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.